Dermata Doses First Patient in Phase 1b Trial of Topical DMT310 for Mild-to-Moderate Psoriasis
Top-line results are expected in the second half 2021.
Dermata Therapeutics, Inc. dosed its first patient in a Phase 1b trial of DMT310 for the treatment of mild-to-moderate psoriasis.
DMT310 is currently being investigated to treat multiple inflammatory skin diseases. It consists of a once-weekly topical treatment with both mechanical and chemical mechanisms of action. The Phase 1b trial will enroll 30 mild-to-moderate psoriasis patients who will receive once-weekly treatments of DMT310 for 12 weeks at 3 clinical sites across the United States.
"Enrolling the first patient in this psoriasis study is a big step towards potentially providing these patients with an effective and safe topical product that only needs to be applied once per week, as there are few effective options for patients with milder disease," states Christopher Nardo, PhD, Dermata's SVP, Development, in a news release. "We believe that DMT310 could offer a differentiated topical treatment of psoriasis with its once weekly application schedule, combined with its multiple mechanisms of actions to treat the multiple symptoms of psoriasis."
DMT310-006 Trial Design
DMT310-006, is a 12-week, multi-center, open-label, proof of concept trial designed to evaluate the safety, tolerability and efficacy of once-weekly dosing of DMT310 in 30 mild-to-moderate psoriasis patients. Patients will receive 12 once-weekly topical treatments of DMT310 and be observed for 12 weeks. The primary endpoints include the Physician's Global Assessment, the Investigator's Psoriasis Area Severity Index and the Pruritis Visual Analog Scale at week 12. Dermata expects to have top-line results in the second half of 2021.
About DMT310
DMT310 is derived from a unique freshwater sponge that is harvested under specific environmental conditions and then processed into a powder. The powder is mixed with fluidizing agent immediately prior to application and only needs to be applied once per week. DMT310's organic components contain chemicals components that when tested in vitro, have shown a dose dependent inhibition of both IL-17A and IL-17F, which are believed to be major effector cytokines in the pathogenesis of psoriasis.